Announcement • Apr 18

Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate

Orum Therapeutics announced the presentation of new preclinical data for ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload, in development for the treatment of AML and other CD123-positive hematological malignancies. The data were presented in two posters at the American Association for Cancer Research Annual Meeting 2026. The first poster (Abstract Number: 1824) highlights how ORM-1153 was engineered with a proprietary CD123-antibody designed for enhanced internalization and reduced Fc-gamma receptor interactions, together with a linker optimized for plasma stability, an approach intended to improve delivery, reduce off-target and immune cell engagement, and support favorable pharmacologic properties. Consistent with that design, ORM-1153 showed strong preclinical anti-leukemia activity at low doses, along with prolonged accumulation in tumors, undetectable systemic free payload, and favorable repeat-dose non-human primate findings supporting a manageable safety and tolerability profile. Data from the second poster (Abstract Number: 1710) extend Orum’s previously presented findings by showing activity across primary AML patient samples and in models with relevant tumor mutations, including TP53. Taken together, the findings support the potential for broad activity in AML, including in patients with TP53 mutations. Both posters are available on Orum’s website and will be presented at AACR on Monday, April 20, from 9 am to 12 pm PDT. ORM-1153 is a CD123-targeting degrader-antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule is built from two proprietary elements, a GSPT1-degrading payload and an anti-CD123 antibody engineered for high internalization efficiency, conjugated with a cleavable ß-glucuronide linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues. Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.

Announcement • Apr 14

Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors

Orum Therapeutics, Inc. announced the appointment of Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board of Directors, following approval at the Company’s Annual General Meeting, which took place March 27, 2026. Orum is advancing GSPT1-directed TPD²® programs and developing novel degrader payloads to expand the potential of DACs in oncology and beyond. Dr. Koehler is an oncology biotech executive, hematologist/oncologist, and board director with more than 20 years of experience across clinical development, regulatory strategy, translational oncology, medical affairs, and biomarker-driven drug development. Most recently, she served as Venture Partner with Omega Funds and Senior Advisor to Viking Global, and until March 2025 was Chief Medical Officer of Repare Therapeutics, where she led clinical, regulatory strategy, and operations. She previously served as Chief Medical Officer of Bicycle Therapeutics and held senior oncology development roles at Pfizer, GSK, and AstraZeneca, including leadership of IBRANCE® (palbociclib) development at Pfizer. Dr. Koehler has played a prominent role in early oncology development and biomarker strategy, has authored more than 170 peer-reviewed publications and chapters, and has served on multiple public and private company boards, including Abdera Therapeutics, REMIX Therapeutics, Ikena, Silverback, and Celyad. Mr. Meyerson is a life science entrepreneur, strategic advisor, and transaction leader with experience spanning biotech investment banking, business development, venture capital, and company creation. He is Co-founder and CEO of Locust Walk, and Co-founder of Franklin Life Science, Venning Life Sciences, and BioBreak. He brings a broad perspective shaped by work across strategic transactions and company-building in the life sciences, with expertise in business development, M&A negotiations and deal structuring, venture capital investing, and growth strategy.

Orum Therapeutics, Inc. Stock Price

A475830 Share Price Performance

A475830 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Orum Therapeutics, Inc. Key Details

About A475830

Recent A475830 News & Updates

We're Hopeful That Orum Therapeutics (KOSDAQ:475830) Will Use Its Cash Wisely

Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate

Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors

Recent updates

Orum Therapeutics, Inc. Competitors

Samsung BiologicsLtd